Advertisement
Product › Details
Norprolac®
Next higher product group | quinagolid (INN) (qm) | |
Status | 1994-01-01 registration start | |
Status | 1997-01-01 sales existent | |
Organisation | Sandoz AG Nürnberg | |
Today | Novartis Pharma GmbH (DE) | |
Group | Novartis (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for CNS drug (neurological drug)
- [1] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
- [2] Merz Asset Management Holding GmbH & Co. KG. (4/2/24). "Press Release: Merz Enters Asset Purchase Agreement with a US-based Biotech Company". Frankfurt am Main....
- [3] Sosei Group Corporation (d/b/a Sosei Heptares). (3/11/24). "Press Release: Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-in-class Treatments Targeting All Symptoms of Schizophrenia". Ingelheim, Tokyo & Cambridge....
- [4] Vandria S.A.. (12/14/23). "Press Release: Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform". Lausanne....
- [5] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
- [6] Secarna Pharmaceuticals GmbH & Co. KG. (3/27/23). "Press Release: Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases". Martinsried....
- [7] Rewind Therapeutics. (1/25/23). "Press Release: Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor". Leuven....
- [8] Cajal Neuroscience. (11/29/22). "Press Release: Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration". Seattle, WA....
- [9] Alto Neuroscience Inc.. (10/25/22). "Press Release: Alto Neuroscience Announces $35 Million Series B Financing". Los Altos, CA....
- [10] Empyrean Neuroscience, Inc.. (10/18/22). "Press Release: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders". New York, NY & Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top